

DAFTAR PUSTAKA

- Abdel-Aziz, A. M., El-Tahawy, N. F. G., Mohammed, M. M., Ali, A. I. & Ibrahim, Y. F. 2020. Amelioration of testosterone-induced benign prostatic hyperplasia using febuxostat in rats: The role of VEGF/TGF β and iNOS/COX-2. *European Journal of Pharmacology*, 889, 173631.
- Adaramoye, O. A., Oladipo, T. D., Akanni, O. O. & Abiola, O. J. 2019. Hexane fraction of *Annona muricata* (Sour sop) seed ameliorates testosterone-induced benign prostatic hyperplasia in rats. *Biomedicine & Pharmacotherapy*, 111, 403-413.
- Ahmad, M., Suhail, N., Mansoor, T., Banu, N. & Ahmad, S. 2012. Evaluation of oxidative stress and DNA damage in benign prostatic hyperplasia patients and comparison with controls. *Indian Journal of Clinical Biochemistry*, 27, 385-388.
- Atawia, R. T., Tadros, M. G., Khalifa, A. E., Mosli, H. A. & Abdel-Naim, A. B. 2013. Role of the phytoestrogenic, pro-apoptotic and anti-oxidative properties of silymarin in inhibiting experimental benign prostatic hyperplasia in rats. *Toxicology letters*, 219, 160-169.
- Barry, M. J. 2001. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. *Urology*, 58, 25-32.
- Chapple, C. R. & Roehrborn, C. G. 2006. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. *European urology*, 49, 651-659.
- Chiba, K., Yamaguchi, K., Li, F., Ando, M. & Fujisawa, M. 2011. Finasteride-associated male infertility. *Fertility and sterility*, 95, 1786. e9-1786. e11.
- Colli, E., Rigatti, P., Montorsi, F., Artibani, W., Petta, S., Mondaini, N., Scarpa, R., Usai, P., Olivieri, L. & Maggi, M. 2006. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. *European urology*, 49, 82-86.
- Crescioli, C., Villari, D., Forti, G., Ferruzzi, P., Petrone, L., Vannelli, G., Adorini, L., Salerno, R., Serio, M. & Maggi, M. 2002. Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue. *Molecular and cellular endocrinology*, 198, 69-75.
- D'arcy, M. S. 2019. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. *Cell biology international*, 43, 582-592.
- El-Sherbiny, M., El-Shafey, M., El-Agawy, M. S. E.-D., Mohamed, A. S., Eisa, N. H. & Elsherbiny, N. M. 2021. Diacerein ameliorates testosterone-induced benign prostatic hyperplasia in rats: Effect on oxidative stress, inflammation and apoptosis. *International Immunopharmacology*, 100, 108082.
- Elmore, S. 2007. Apoptosis: a review of programmed cell death. *Toxicologic pathology*, 35, 495-516.
- Elsherbini, D. M. A., Almohaimed, H. M., El-Sherbiny, M., Mohammedsahleh, Z. M., Elsherbiny, N. M., Gabr, S. A. & Ebrahim, H. A. 2022. *Origanum majorana* L. Extract attenuated benign prostatic hyperplasia in rat model: Effect on oxidative stress, apoptosis, and proliferation. *Antioxidants*, 11, 1149.

- Flynn, J. M. & Melov, S. 2013. SOD2 in mitochondrial dysfunction and neurodegeneration. *Free Radical Biology and Medicine*, 62, 4-12.
- Foster, C. 2000. Pathology of benign prostatic hyperplasia. *The Prostate*, 45, 4-14.
- Gacci, M., Corona, G., Salvi, M., Vignozzi, L., Mcvary, K. T., Kaplan, S. A., Roehrborn, C. G., Serni, S., Mirone, V. & Carini, M. 2012. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α -blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. *European urology*, 61, 994-1003.
- Gann, P. H., Hennekens, C. H., Grodstein, F., Stampfer, M. J., Longcope, C. & Verhoek-Oftedahl, W. 1995. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. *The Prostate*, 26, 40-49.
- Geovanni Espinosa, N., Esposito, R., Kazzazi, A. & Djavan, B. 2013. Vitamin D and benign prostatic hyperplasia-a review. *Can J Urol*, 20, 6821.
- Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-Mcginley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R. & Tenover, J. S. 1992. The effect of finasteride in men with benign prostatic hyperplasia. *New England Journal of Medicine*, 327, 1185-1191.
- Guess, H., Arrighi, H., Metter, E. & Fozard, J. 1990. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. *The Prostate*, 17, 241-246.
- Haghsheno, M.-A., Mellström, D., Behre, C.-J., Damber, J.-E., Johansson, H., Karlsson, M., Lorentzon, M., Peeker, R., Barret-Connor, E. & Waern, E. 2013. Low 25-OH vitamin D is associated with benign prostatic hyperplasia. *The Journal of urology*, 190, 608-614.
- Hamasaki, T., Inatomi, H., Katoh, T., Ikuyama, T. & Matsumoto, T. 2002. Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. *Urologia internationalis*, 68, 226-231.
- Hanchette, C. L. & Schwartz, G. G. 1992. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. *Cancer*, 70, 2861-2869.
- Holick, M. F. 2010. *Vitamin D: physiology, molecular biology, and clinical applications*, Springer Science & Business Media.
- Huang, Y., Chen, H., Zhou, X., Wu, X., Hu, E. & Jiang, Z. 2017. Inhibition effects of chlorogenic acid on benign prostatic hyperplasia in mice. *European Journal of Pharmacology*, 809, 191-195.
- Igney, F. H. & Krammer, P. H. 2002. Death and anti-death: tumour resistance to apoptosis. *Nature Reviews Cancer*, 2, 277-288.
- Ismy, J., Sugandi, S., Rachmadi, D., Hardjowijoto, S. & Mustafa, A. 2020. The effect of exogenous superoxide dismutase (SOD) on caspase-3 activation and apoptosis induction in Pc-3 prostate cancer cells. *Research and Reports in Urology*, 503-508.
- Jemal, A., Tiwari, R. C., Murray, T., Ghafour, A., Samels, A., Ward, E., Feuer, E. J. & Thun, M. J. 2004. Cancer statistics, 2004. *CA-ATLANTA*, 54, 8-29.

- Jin, B.-R. & An, H.-J. 2020. Baicalin alleviates benign prostate hyperplasia through androgen-dependent apoptosis. *Aging (Albany NY)*, 12, 2142.
- Kim, K. S., Yang, H. Y., Chang, S. C., Kim, Y. M., Lee, K. Y., Lee, B. M. & Kim, H. S. 2018. Potential repositioning of GV1001 as a therapeutic agent for testosterone-induced benign prostatic hyperplasia. *International Journal of Molecular Medicine*, 42, 2260-2268.
- Kirby, R. S., McConnell, J. D., Fitzpatrick, J. M., Roehrborn, C. G. & Boyle, P. 2004. *Textbook of benign prostatic hyperplasia*, CRC Press.
- Li, J., Tian, Y., Guo, S., Gu, H., Yuan, Q. & Xie, X. 2018. Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. *PLoS one*, 13, e0191469.
- Lisse, T. S. 2020. Vitamin D regulation of a SOD1-to-SOD2 antioxidative switch to prevent bone cancer. *Applied Sciences*, 10, 2554.
- Liu, X., Zhang, L., Wang, P., Li, X., Qiu, D., Li, L., Zhang, J., Hou, X., Han, L. & Ge, J. 2017. Sirt3-dependent deacetylation of SOD2 plays a protective role against oxidative stress in oocytes from diabetic mice. *Cell cycle*, 16, 1302-1308.
- Lung, B. E., Mowery, M. L. & Komatsu, D. E. E. 2018. Calcitriol.
- Manchanda, P. K., Konwar, R., Nayak, V. L., Singh, V. & Bid, H. K. 2010. Association of genetic variants of the vitamin D receptor (VDR) gene (Fok-I, Taq-I and Bsm-I) with susceptibility of benign prostatic hyperplasia in a North Indian population. *Asian Pac J Cancer Prev*, 11, 1005-1008.
- Mbaka, G., Ogbonnia, S., Sulaiman, A. & Osiagwu, D. 2019. Histomorphological effects of the oil extract of *Sphenocentrum jollyanum* seed on benign prostatic hyperplasia induced by exogenous testosterone and estradiol in adult Wistar rats. *Avicenna journal of phytomedicine*, 9, 21.
- Merke, J., Milde, P., Lewicka, S., Hugel, U., Klaus, G., Mangelsdorf, D. J., Haussler, M. R., Rauterberg, E. W. & Ritz, E. 1989. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. *J Clin Invest*, 83, 1903-15.
- Miller, A.-F. 2012. Superoxide dismutases: ancient enzymes and new insights. *FEBS letters*, 586, 585-595.
- Murphy, A. B., Nyame, Y. A., Batai, K., Kalu, R., Khan, A., Gogana, P., Dixon, M., Macias, V., Kajdacsy-Balla, A. & Hollowell, C. 2017. Does prostate volume correlate with vitamin D deficiency among men undergoing prostate biopsy? *Prostate cancer and prostatic diseases*, 20, 55-60.
- O'Neill, A. J., Boran, S. A., O'Keane, C., Coffey, R. N., Hegarty, N. J., Hegarty, P., Gaffney, E. F., Fitzpatrick, J. M. & Watson, R. W. G. 2001. Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma. *The Prostate*, 47, 183-188.
- Rani, M. P., Anupama, N., Sreelekshmi, M. & Raghu, K. 2018. Chlorogenic acid attenuates glucotoxicity in H9c2 cells via inhibition of glycation and PKC α upregulation and safeguarding innate antioxidant status. *Biomedicine & Pharmacotherapy*, 100, 467-477.

- Roehrborn, C. 2008. Pathology of benign prostatic hyperplasia. *International journal of impotence research*, 20, S11-S18.
- Roehrborn, C. G. 2005. Benign prostatic hyperplasia: an overview. *Reviews in urology*, 7, S3.
- Sasi, N., Hwang, M., Jaboin, J., Csiki, I. & Lu, B. 2009. Regulated cell death pathways: new twists in modulation of BCL2 family function. *Molecular cancer therapeutics*, 8, 1421-1429.
- Schwartz, G. G. Vitamin D in health and disease: vitamin D and the epidemiology of prostate cancer. *Seminars in dialysis*, 2005. Wiley Online Library, 276-289.
- Taniguchi, K., Katagiri, K., Kashiwagi, H., Harada, S., Sugimoto, Y., Shimizu, Y., Arakawa, H., Ito, T., Yamazaki, M. & Watanabe, T. 2010. A novel nonsecosteroidal VDR agonist (CH5036249) exhibits efficacy in a spontaneous benign prostatic hyperplasia beagle model. *The Journal of Steroid Biochemistry and Molecular Biology*, 121, 204-207.
- Tao, R., Coleman, M. C., Pennington, J. D., Ozden, O., Park, S.-H., Jiang, H., Kim, H.-S., Flynn, C. R., Hill, S. & McDonald, W. H. 2010. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. *Molecular cell*, 40, 893-904.
- Thorpe, A. & Neal, D. 2003. Benign prostatic hyperplasia. *The Lancet*, 361, 1359-1367.
- Tiwari, A., Krishna, N., Nanda, K. & Chugh, A. 2005. Benign prostatic hyperplasia: an insight into current investigational medical therapies. *Expert opinion on investigational drugs*, 14, 1359-1372.
- Uygur, M., Gür, E., Arik, A., Altuğ, U. & Erol, D. 1998. Erectile dysfunction following treatments of benign prostatic hyperplasia: a prospective study. *Andrologia*, 30, 5-10.
- Wanner, E., Thoppil, H. & Riabowol, K. 2021. Senescence and apoptosis: architects of mammalian development. *Frontiers in cell and developmental biology*, 8, 620089.
- Yuan, J., Liu, Y., Yang, Z., Qin, X., Yang, K. & Mao, C. 2013. The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews. *Current medical research and opinion*, 29, 279-287.
- Zendehdel, A., Ansari, M., Khatami, F., Mansoursamaei, S. & Dialameh, H. 2021. The effect of vitamin D supplementation on the progression of benign prostatic hyperplasia: A randomized controlled trial. *Clinical Nutrition*, 40, 3325-3331.